MJM: Please describe how your divide you practice on a week-to-week basis. Dr. Saba: I work about one week a month doing hospitalization at the Lachine Hospital in Montreal. I do another week of mixed hospitalization, either with intensive care or without intensive care. I do about two weeks a month altogether in practice at my clinic; I try to be in my office at least three weeks out of four, ...

CRTH2: Chemoattractant Receptor-Homologous Molecule Expressed On Th2 Cells; COPD: Chronic Obstructive Pulmonary Disease; WHO: World Health Organization; SIT: Allergen-Specific Immunotherapy; ICS: Inhaled Corticosteroids; LABA: LongActing-Β-Agonist; SABA: Short-Acting-Β-Agonist; MDI: Metered Dose Inhaler; 5-LO: 5-Lipoxygenase; FLAP: 5-LipoxygenaseActivating Protein; 5-Oxo-ETE: 5-Oxo-6,8,11,14-Ei...

Background: Asthma is a chronic inflammatory disease, therefore inhaled corticosteroid (ICS) should be as the cornerstone of asthma treatment. However patients tend to rely on short-acting β2-agonist (SABA) due immediate symptom relief and underuse ICS, thereby undertreating underlying inflammation. As part multi-country SABA use IN (SABINA) III study, we aimed describe prescription patterns as...

OBJECTIVE To compare asthma-related health care resource utilization among a matched cohort of asthma patients using inhaled corticosteroids (ICSs) plus either montelukast (MON) or salmeterol (SAL) as combination therapy for asthma, during a time prior to the availability of fixed-dose combinations of ICS/SAL. METHODS A retrospective analysis using the PHARMetrics patient-centric claims datab...